J Clin Psychiatry 2000;61(11):874-875 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: In their recent article (1999, Supplement 20) reporting results from a double-blind randomized treatment of late-life depression, Mulsant et al. found a lack of statistically significant difference between the rates of response to nortriptyline and paroxetine. The authors report that over 6 weeks of treatment, the tolerability of and response to therapeutic plasma drug levels were similar in their patients, irrespective of inpatient versus outpatient status or the presence or absence of melancholia. As the authors noted, these results are in discord with several reports including 2 multicenter, double-blind studies from the Danish University Antidepressant Group and 1 from the New York State Psychiatric Institute (NYSPI).